Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

The Department of Obstetrics and Gynecology (General Gynecology Center/Gynecological Pelvic Floor Diagnosis and Treatment Center) is the core of this interdisciplinary integrated diagnosis and treatment system, which is jointly developed with teams from other disciplines such as Rehabilitation Medicine and Maternal and Infant Specialty Nursing. Led by Academician Zhu Lan, this system is characterized by its "cooperative" pelvic floor reconstruction surgery and the theory of postpartum pelvic floor screening, rehabilitation, and prevention at the source. It is positioned as the leading unit of the national three-tiered prevention and treatment network for pelvic floor diseases and a guidance center for the prevention and treatment of complex pelvic floor diseases. In the Fudan University's comprehensive ranking of Chinese hospital specialties, the Department of Obstetrics and Gynecology has maintained its position as number one nationwide for 12 consecutive years.

Historical Origins and Spiritual Inheritance:

The Department of Obstetrics and Gynecology at Peking Union Medical College Hospital was established upon the hospital's founding in 1921, with Dr. Lin Qiaozhi as its first Chinese director. Professor Ke Yingkui, who graduated in 1933, conducted in-depth research on the Chinese female pelvis, while Professor Liu Zhufeng accumulated rich experience in vaginal surgery. In the late 1990s, Academician Lang Jinghe and Professor Zhu Lan founded and developed the Department of Gynecologic Urology in China. In 2005, they spearheaded the establishment of the Gynecologic Pelvic Floor Group of the Chinese Medical Association's Obstetrics and Gynecology Society. The Peking Union Medical College Hospital team has achieved outstanding results in basic research, epidemiology, clinical research, and translational research on pelvic floor diseases, winning the second prize of the National Science and Technology Progress Award in 2019.

Core business operational efficiency:

As the only national center specializing in the prevention and treatment of complex pelvic floor dysfunction, it has collaboratively introduced European models for pelvic floor disease screening and rehabilitation, adapting them to China's national conditions. This has led to the establishment of a three-tiered network management model for pelvic floor disease screening and treatment in China—comprising 42 treatment centers, 179 prevention centers, and 296 screening centers nationwide. The center has also formulated clinical diagnostic and treatment guidelines for pelvic floor rehabilitation in China. As of June 2017, over 6 million people had been screened, and over 3 million had received treatment. The International Medical Department's Pelvic Floor Rehabilitation Treatment Room provides pelvic floor muscle assessment, biofeedback training, and electrical stimulation therapy to women 42 days postpartum.

Discipline Positioning and Benchmarking:

Professor Zhu Lan initiated and established the Chinese gynecological pelvic floor specialty, perfected the theory of pelvic floor anatomical reconstruction and functional recovery, and pioneered pelvic floor reconstruction techniques such as the "concordant" method. This increased the success rate of pelvic organ prolapse surgery from 54% to over 95%, and reduced the complication rate from 11.4% to 2.4%. She also pioneered a Chinese model for the prevention and treatment of pelvic floor diseases, and the widespread adoption of postpartum pelvic floor rehabilitation in China has reduced the prevalence of urinary incontinence among adult women from 31% to 16%. Professor Zhu Lan was elected an academician of the Chinese Academy of Sciences in 2025. She led the establishment of a contingency group for congenital reproductive tract malformations, a rare pelvic floor disease with the widest distribution and largest number of patients in 22 well-known hospitals in 7 developed countries including China, the United States, and Europe. Her clinical research results have been included in 7 international guidelines. She has won the Ho Leung Ho Lee Prize and the Tan Jia Zhen Prize, and was selected as one of the top 2% of scientists in the world in 2024.

One of the core subspecialties under the Department of Rehabilitation Medicine. This subspecialty takes early rehabilitation intervention in the ICU as its core concept and the prevention and treatment of post-intensive care syndrome (PICS) as its key goal. Relying on the comprehensive advantages of Peking Union Medical College Hospital as a national guidance center for the diagnosis and treatment of complex and critical illnesses, it is positioned as a national clinical demonstration and standard output center for critical care rehabilitation, and carries out clinical, teaching and research work within the overall framework of the Department of Rehabilitation Medicine.

Historical Origins and Spiritual Inheritance:

The Department of Rehabilitation Medicine originated from the physiotherapy room founded in 1921 by Professor Andrew H. Woods, then head of the Department of Neurology. In 1932, it became an independent physiotherapy department founded by American physiotherapist Mary McMillan, making it one of the birthplaces of modern rehabilitation medicine in China. Critical care rehabilitation, as a subspecialty, is rooted in the department's core principle of "functional recovery as the ultimate goal." In 2017, the department officially published an introduction to the Critical Care Rehabilitation Group on the Peking Union Medical College Hospital website, systematically explaining the effectiveness, safety, and feasibility of early ICU rehabilitation. It advocates that early rehabilitation treatment for ICU patients should be conducted simultaneously with disease treatment, and recommends that patients be evaluated for rehabilitation treatment within 24 hours of admission to the ICU. The implementation of this concept marks a paradigm shift for Peking Union Medical College Hospital's critical care rehabilitation from the traditional "rehabilitation after transfer out of the ICU" model to the "simultaneous rehabilitation within the ICU" model.

Core business operational efficiency:

The Department of Rehabilitation Medicine currently has 7 rehabilitation physicians and 25 rehabilitation therapists. Its subspecialties are comprehensive, with critical care rehabilitation listed alongside musculoskeletal rehabilitation, neurological rehabilitation, cardiac rehabilitation, pulmonary rehabilitation, hemophilia rehabilitation, and rare disease rehabilitation as core subspecialties. The Critical Care Rehabilitation Group routinely conducts early activity and rehabilitation assessments for ICU patients, covering multiple critical care units including internal medicine ICU, surgical ICU, and neurological ICU. The department has conducted a clinical study (June-August 2020, 20 cases) on EIT monitoring of changes in lung ventilation during early activity in ARDS patients with difficulty weaning from ventilators, exploring strategies to optimize respiratory monitoring during early activity in critically ill patients using impedance tomography. In addition, the department explored the use of skeletal robots to assist adolescent patients with high-level spinal cord injuries in early activity and rehabilitation intervention, expanding the technological boundaries of critical care rehabilitation.

Discipline Positioning and Benchmarking:

The Department of Rehabilitation Medicine is an independent clinical department with fully functional areas including physical therapy, rehabilitation assessment, physical therapy and occupational therapy, hydrotherapy, massage therapy, and speech and cognitive therapy, providing a solid platform for critical care rehabilitation. The department maintains long-term exchange and cooperation with WFH, the International Study Group on Prevention and Treatment (IPSG), Toronto Children's Hospital, UCSF, and Johns Hopkins Geriatrics Center. Three staff members have been selected for the hospital's "Hundred Talents Program" to study at institutions such as the University of California, San Francisco, Mount Sinai School of Medicine, and the University of Chicago Medical Center, introducing internationally advanced rehabilitation management concepts and new technologies to China. In the field of critical care rehabilitation, the department is characterized by evidence-based early activity protocols and a multidisciplinary collaborative model, benchmarking against advanced international practices in early ICU rehabilitation.

One of the core subspecialties under the Department of Rehabilitation Medicine. This subspecialty takes early rehabilitation intervention in the ICU as its core concept and the prevention and treatment of post-intensive care syndrome (PICS) as its key goal. Relying on the comprehensive advantages of Peking Union Medical College Hospital as a national guidance center for the diagnosis and treatment of complex and critical illnesses, it is positioned as a national clinical demonstration and standard output center for critical care rehabilitation, and carries out clinical, teaching and research work within the overall framework of the Department of Rehabilitation Medicine.

Historical Origins and Spiritual Inheritance:

The Department of Rehabilitation Medicine originated from the physiotherapy room founded in 1921 by Professor Andrew H. Woods, then head of the Department of Neurology. In 1932, it became an independent physiotherapy department founded by American physiotherapist Mary McMillan, making it one of the birthplaces of modern rehabilitation medicine in China. Critical care rehabilitation, as a subspecialty, is rooted in the department's core principle of "functional recovery as the ultimate goal." In 2017, the department officially published an introduction to the Critical Care Rehabilitation Group on the Peking Union Medical College Hospital website, systematically explaining the effectiveness, safety, and feasibility of early ICU rehabilitation. It advocates that early rehabilitation treatment for ICU patients should be conducted simultaneously with disease treatment, and recommends that patients be evaluated for rehabilitation treatment within 24 hours of admission to the ICU. The implementation of this concept marks a paradigm shift for Peking Union Medical College Hospital's critical care rehabilitation from the traditional "rehabilitation after transfer out of the ICU" model to the "simultaneous rehabilitation within the ICU" model.

Core business operational efficiency:

The Department of Rehabilitation Medicine currently has 7 rehabilitation physicians and 25 rehabilitation therapists. Its subspecialties are comprehensive, with critical care rehabilitation listed alongside musculoskeletal rehabilitation, neurological rehabilitation, cardiac rehabilitation, pulmonary rehabilitation, hemophilia rehabilitation, and rare disease rehabilitation as core subspecialties. The Critical Care Rehabilitation Group routinely conducts early activity and rehabilitation assessments for ICU patients, covering multiple critical care units including internal medicine ICU, surgical ICU, and neurological ICU. The department has conducted a clinical study (June-August 2020, 20 cases) on EIT monitoring of changes in lung ventilation during early activity in ARDS patients with difficulty weaning from ventilators, exploring strategies to optimize respiratory monitoring during early activity in critically ill patients using impedance tomography. In addition, the department explored the use of skeletal robots to assist adolescent patients with high-level spinal cord injuries in early activity and rehabilitation intervention, expanding the technological boundaries of critical care rehabilitation.

Discipline Positioning and Benchmarking:

The Department of Rehabilitation Medicine is an independent clinical department with fully functional areas including physical therapy, rehabilitation assessment, physical therapy and occupational therapy, hydrotherapy, massage therapy, and speech and cognitive therapy, providing a solid platform for critical care rehabilitation. The department maintains long-term exchange and cooperation with WFH, the International Study Group on Prevention and Treatment (IPSG), Toronto Children's Hospital, UCSF, and Johns Hopkins Geriatrics Center. Three staff members have been selected for the hospital's "Hundred Talents Program" to study at institutions such as the University of California, San Francisco, Mount Sinai School of Medicine, and the University of Chicago Medical Center, introducing internationally advanced rehabilitation management concepts and new technologies to China. In the field of critical care rehabilitation, the department is characterized by evidence-based early activity protocols and a multidisciplinary collaborative model, benchmarking against advanced international practices in early ICU rehabilitation.

The Department of Psychiatry at Peking Union Medical College Hospital is the first secondary-level psychiatry specialty established under the clinical medicine department of a general hospital in China. It was founded by Professor Wei Jing in May 2006. The department is a vice-chairman unit of the Behavioral Medicine Branch of the Chinese Medical Association, a chairman unit of the Psychosomatic Medicine Branch of the Beijing Medical Association, and a vice-president unit of the Psychiatry Branch of the Chinese Medical Doctor Association. With psychosomatic medicine as its core concept and the integration of psychotherapy and pharmacological treatment as its diagnostic and treatment characteristics, it is positioned as the source of China's general hospital mental health service model and a core base for the training of psychosomatic medicine professionals nationwide.

Historical Origins and Spiritual Inheritance. The department was reorganized and established in May 2006, based on the Psychophysiology Center of Peking Union Medical College Hospital. In May 2013, the Department of Psychiatry and Mental Health of Peking Union Medical College was established, setting up a Master's and Doctoral degree program, with Professor Wei Jing serving as its first department head. The department first integrated clinical diagnosis and treatment and services of mental health into the comprehensive hospital's medical system, and improved its talent training system, creating the first secondary-level mental health specialty under clinical medicine in China. Professor Wei Jing has worked in the field of psychiatry/psychology in general hospitals for more than 20 years. He was a senior visiting scholar at Harvard Medical School in the United States from 1997 to 1998 and was appointed as a visiting lecturer in the Department of Medicine at Harvard Medical School.

Core business operational efficiency:

The department operates on the core principles of psychosomatic medicine, combining psychotherapy with medication to provide support to visitors suffering from psychological or emotional distress, patients experiencing unresolved emotional problems or physical functional symptoms due to mental illness, and patients and their families suffering psychological torment from chronic or severe illnesses. The department offers outpatient services including basic prescription and outpatient consultations, counseling services, individual and group therapy services, as well as inpatient and outpatient liaison consultations. In 2026, the hospital initiated the preparatory work for the Psychological Health and Mental Health Medical Center, led by the Department of Psychiatry and jointly constructed with 15 other departments, including Neurology, Endocrinology, and Cardiology, highlighting its multidisciplinary collaborative diagnosis and treatment approach. Professor Wei Jing pioneered the course "Medical Clinical Communication Skills" in 2007 and was the first to introduce and promote the "Balint Group," a professional doctor-patient relationship work mechanism, to China, training more than 100,000 medical workers nationwide.

Discipline Positioning and Benchmarking:

It is a vice-chairman unit of the Behavioral Medicine Branch of the Chinese Medical Association, a chairman unit of the Psychosomatic Medicine Branch of the Beijing Medical Association, a vice-president unit of the Psychiatry Branch of the Chinese Medical Doctor Association, and a vice-chairman unit of the Psychosomatic Medicine Professional Committee of the Chinese Mental Health Association. Professor Wei Jing serves as the director of the Department of Psychiatry at Peking Union Medical College Hospital, the director of the Mental Health and Mental Health Medical Center (in preparation), and the director of the Department of Psychiatry and Mental Health at Peking Union Medical College. In 2024, he received the "20th Beijing Higher Education Teaching Master Award".

Designated by the National Health Commission as the National Guidance Center for the Diagnosis and Treatment of Complex and Critical Illnesses; the only national-level leading unit of the National Rare Disease Diagnosis and Treatment Collaboration Network; the first comprehensive rare disease medical discipline in China; a national key laboratory for complex and critical illnesses and rare diseases; constructing a one-stop MDT diagnosis and treatment system for complex and difficult diseases of unknown cause, rare diseases involving multiple systems, and complex and critical illnesses across disciplines; benchmarked against the NIH Rare Disease Research Center and the Mayo Clinic in the United States.

The National Health Commission's National Guidance Center for the Diagnosis and Treatment of Difficult, Severe, and Rare Diseases; the first independently established rare disease medical department in China, equipped with a consultation center for difficult and severe diseases, a national-level rare disease MDT platform, and a national key laboratory for difficult, severe, and rare diseases; benchmarked against top international rare disease centers (US NIH Undiagnosed Diseases Program UDN Center, UK London Rare Disease Centre), it is a national benchmark for the diagnosis, quality control, and scientific research transformation of difficult and rare diseases in China, and the hospital has the highest CMI case difficulty index in the country.

Historical Origins and Spiritual Inheritance:

Since its founding in 1921, the hospital has established a tradition of discussing difficult cases, inheriting the spirit of "rigor, precision, diligence, and dedication." Predecessors such as Zhang Xiaoqian laid the foundation for a "clinical-based, analytical and evidence-based" paradigm for the diagnosis and treatment of difficult diseases. The Internal Medicine Grand Rounds and Clinical Pathology Conference (CPC) have continued for over a century. In 2010, a multi-system difficult disease consultation center was established. In 2019, a national-level rare disease MDT consultation platform was built. In 2023, the first fully-fledged rare disease medical department in China was established. Simultaneously, a national key laboratory for difficult and severe illnesses and rare diseases was constructed.

Core business operational efficiency:

The Department of Rare Diseases is a platform-based department, with a joint outpatient clinic, specialist wards, and a genetic consultation platform. The wards admit undiagnosed disease (UDN) cases with an admission confirmation rate of 59%. The MDT consultation covers cases referred nationwide, and the online remote consultation system radiates to more than 400 collaborating hospitals across the country. It leads the national rare disease diagnosis and treatment collaboration network, constructs clinical queues and biobanks, and realizes integrated operation of medical treatment, teaching, research, and translation, shortening the average diagnosis cycle of rare diseases from 4 years to about 4 weeks.

Core strengths:

Breaking down departmental barriers, it adopts the "multiple experts surrounding a single patient" MDT model; it possesses the rare domestic capability for systematic diagnosis of unexplained diseases (UDN); it has a complete closed loop encompassing clinical, pathological, imaging, genetic, and translational medicine; and it has a complete subspecialty system throughout the hospital, enabling the rapid assembly of cross-system expert teams. **Discipline Positioning and Global Benchmarking**: National-level Guidance Center for the Diagnosis and Treatment of Complex, Severe, and Rare Diseases; benchmarking against the US NIH UDN Center and the Great Ormond Street Rare Disease Centre in London, UK; differentiating itself from overseas centers that emphasize basic research, it integrates clinical diagnosis and treatment, national quality control, remote collaboration, and a unified approach to the Chinese population to build a diagnosis and treatment system for complex and rare diseases suitable for the Chinese population, and export the "core business operation efficiency MDT system" for large-scale operation of rare diseases. Currently, the consultation center brings together 60 departments and 900 experts with associate senior or higher professional titles, forming 55 MDT (Multidisciplinary Team) professional groups. It has completed over 5,000 consultations, serving more than 20,000 patients, with over 80% of these patients coming from outside Beijing, covering 29 provinces, autonomous regions, and municipalities across the country. Rare disease MDT case discussions are broadcast live nationwide every Thursday at noon, attracting over 100 hospitals and thousands of online viewers on average.

Key performance indicators:

The diagnosis cycle for patients with rare diseases has been drastically shortened from an average of 4 years to less than 4 weeks;

The average treatment cost for patients with rare diseases nationwide has decreased by 90%, the multidisciplinary team (MDT) implementation rate has increased from 25% to 68%, and drug accessibility has increased from 27.2% to 41.1%.

The rare disease ward has admitted 329 patients in its first year of operation. Among the 83 patients admitted without a diagnosis, 49 were successfully diagnosed, achieving a diagnosis rate of 59%, with zero errors, zero complaints, and zero deaths.

This department is a pioneering unit in the treatment of internal oncology in China, a key clinical specialty construction project department of the National Health Commission, one of the first batch of pilot departments for multidisciplinary oncology diagnosis and treatment by the National Health Commission, and one of the first batch of specialized research wards in Beijing's demonstration construction unit for research-oriented wards. With "standardized oncology treatment" as its core concept, the department focuses on precision targeted therapy, immunotherapy, and cell therapy (CAR-T/TCR-T) as its cutting-edge breakthrough directions. Its differentiated advantage lies in the diagnosis and treatment of rare tumors, tumors in the elderly, and complex and difficult cases of tumors with underlying diseases. It is positioned as a national center for standardized diagnosis and treatment and innovative treatment of solid tumors.

Historical Origins and Spiritual Inheritance:

Professor Sun Yan, an academician of the Chinese Academy of Engineering, is the founder of the field of oncology in my country. He received his doctorate from Peking Union Medical College in 1956 and was commissioned to establish a brand-new discipline of oncology in 1959. Starting with 5 beds, he established a comprehensive breast cancer ward in 1960 and formally established an internal medicine ward in 1965. By 1965, the number of beds had increased to more than 30 and the team of 5 young doctors had grown. Professor Sun Yan led his team to achieve international advanced standards in the comprehensive treatment of lymphoma, small cell lung cancer, and testicular tumors. He published more than 380 papers and compiled 42 books on oncology. He was the first to use modern scientific methods to elucidate the immunomodulatory effects of traditional Chinese medicine for strengthening the body. After studying in the United States in 1979, he returned to China and promoted the establishment of CSCO (Chinese Society of Clinical Oncology) in 1997, which brought Chinese clinical oncology fully in line with international standards.

The Department of Oncology at Peking Union Medical College Hospital continues the academic foundation laid by Academician Sun Yan. In November 2001, the department was among the first in large comprehensive hospitals nationwide to establish a chemotherapy ward, and in August 2002, it officially became an independent department. Under the leadership of three generations of department directors—Professor Chen Shuchang, Professor Bai Chunmei, and Professor Ba Yi—the department adheres to the Peking Union Medical College spirit of "rigor, excellence, diligence, and dedication." It is one of the first departments in China to propose the concept of "standardized cancer treatment," navigating the complexities of cancer treatment and following advanced treatment models such as "individualized treatment," "multidisciplinary collaboration," and "precision anti-cancer therapy."

Core business operational efficiency:

The department currently has three wards: the Oncology Ward 1 (West Campus), the Oncology and Hematology Ward 2, and the Outpatient Chemotherapy Area. It sees over 60,000 outpatients and 6,000 inpatients annually, with an annual outpatient volume exceeding 70,000 (including day chemotherapy). The department undertakes national and Beijing municipal medical tasks such as healthcare for high-ranking officials and medical assistance to Macao and border regions. The Xidan campus's day chemotherapy outpatient clinic has 15 chemotherapy beds and can see 50 to 60 outpatients daily. Inpatient chemotherapy requires at least three days from admission to discharge, while day chemotherapy patients can go home after a three-hour infusion. As a national-level clinical trial base for oncology drugs, the department conducts more than 20 phase I to IV clinical trials of oncology drugs annually, and designs, undertakes, and participates in more than 200 global and national multicenter clinical studies, contributing to the approval of many new drugs for clinical use.

Discipline Positioning and Benchmarking:

The department is a key clinical specialty construction project department of the National Health Commission, one of the first batch of pilot departments for multidisciplinary oncology diagnosis and treatment of tumors of the National Health Commission, one of the first batch of specialized research wards of Beijing's demonstration construction unit for research-oriented wards, and the leading unit of the Dongcheng District Tumor Treatment and Xicheng District Tumor Prevention and Control Quality Control and Improvement Center. As the tumor quality control center of Dongcheng District and Xicheng District of Beijing, the department has established standardized procedures to ensure the homogenization of common tumor treatment at the grassroots level. Complex cases are treated by Peking Union Medical College Hospital and then transferred back to the grassroots level for follow-up through a two-way referral mechanism. The department has established academic ties with world-class cancer research institutions such as MD Anderson, Mayo Clinic, Johns Hopkins, UCLA, UCSF, Cancer Institute Hospital of Japan, and National Cancer Center of Japan.

A national key clinical specialty; consistently ranked second in the national ranking of gastroenterology in Fudan University's specialty reputation list; one of the birthplaces of modern gastroenterology in China; National Center for the Diagnosis and Treatment of Complex and Critical Digestive Diseases; comprising a Gastrointestinal Endoscopy Center, a Pancreatic Disease Center, an Inflammatory Bowel Disease (IBD) Center, and a Gastrointestinal Motility Center; has established an MDT system for complex digestive diseases; and is benchmarked against the Department of Gastroenterology at Johns Hopkins Hospital in the United States.

Historical Origins and Spiritual Inheritance :

The Department of Gastroenterology is one of the earliest established specialties at Peking Union Medical College Hospital, personally led and nurtured by Professor Zhang Xiaoqian, a leading figure in modern internal medicine in my country, and Professor Chen Minzhang, a renowned expert in gastroenterology. In 1930, Professor Zhang Xiaoqian established the Department of Gastroenterology, opening my country's first specialized gastroenterology outpatient clinic. In the 1970s, Professor Chen Minzhang pioneered the introduction of fiber endoscopy and colonoscopy in China, performing the country's first ERCP, and is hailed as the founder of my country's gastrointestinal endoscopy. Professor Zhang Xiaoqian adopted the phrase "as if facing a deep abyss, as if treading on thin ice" from the Book of Songs as his medical philosophy, deeply imprinting it into the department's cultural DNA.

Core business operational efficiency :

The department boasts a comprehensive range of subspecialties, including nationally recognized centers for the diagnosis and treatment of inflammatory bowel disease and pancreatic diseases, a gastrointestinal endoscopy training center, and a gastrointestinal motility disorder diagnosis and treatment center. In the Fudan University's ranking of Chinese hospital specialty reputations, the Department of Gastroenterology has consistently ranked among the top in the country (second place). The department possesses the largest IBD (Infectious Diseases) ward in Northern my country, with IBD-related cases accounting for 47.82% of all cases.

Discipline Positioning and Benchmarking :

Designated as one of the first batch of key clinical specialties in China, this leading institution in the field of gastroenterology is positioned as a high-level center for the diagnosis and treatment of gastroenterology, endoscopy, and complex and critical illnesses. Internationally, the discipline has achieved a leading position in the field of inflammatory bowel disease (IBD) in Asia and even globally. Professor Qian Jiaming received the "Asia AOCC 2026 Leadership Legacy Award," signifying high international recognition of China's IBD diagnosis and treatment research.

The Department of Gastrointestinal Surgery at Peking Union Medical College Hospital is one of the core subspecialties under the Department of General Surgery. Established in 1921, the Department of General Surgery is one of the oldest departments at Peking Union Medical College Hospital, a key clinical specialty designated by the National Health Commission, and has ranked first in the Fudan University's "China Hospital Specialty Ranking" for 12 consecutive years. The Gastrointestinal Surgery subspecialty focuses on minimally invasive surgical treatment of benign and malignant gastrointestinal tumors, specializing in gastrointestinal surgery and nutritional metabolism. It is a leading department in China and an advanced subspecialty internationally in radical gastrectomy, radical colorectal resection, and laparoscopic minimally invasive techniques.

Historical Origins and Spiritual Inheritance:

In the early 1980s, renowned surgeon Professor Tseng Hsien-jiu established some of the earliest specialized groups in China based on the characteristics of his discipline, including pancreatic, gastrointestinal, breast, hepatobiliary, surgical nutrition, intensive care unit (ICU), and related clinical laboratories. Professor Tseng served as the head of the Department of Surgery at Peking Union Medical College Hospital from 1956 onwards, and was hailed by international surgical colleagues as "a guiding light in the world of surgery." Under the leadership of Professors Zhu Yu, Zhao Yuping, and Qiu Huizhong, the subspecialty system was gradually improved, and in 2012 it became a national key clinical specialty. The gastrointestinal group's main research areas are gastrointestinal surgery and clinical parenteral and enteral nutrition therapy, and it was among the first in China to perform radical gastrectomy for gastric cancer.

Core business operational efficiency:

The Department of General Surgery currently has 4 wards, 1 laboratory, and 2 affiliated wards, handling over 100,000 outpatient and emergency visits and performing over 8,000 surgeries annually. It admits over 30,000 inpatients and outpatients annually, performing nearly 16,000 surgeries. The gastrointestinal specialist group performs an average of 250-300 colorectal cancer surgeries annually. The department prioritizes the treatment of patients requiring complex surgeries, with level IV surgeries consistently accounting for around 80% of all surgeries.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty and a key discipline in Beijing. The hospital is a member unit of the Chinese Medical Association, with Academician Zhao Yuping of the Chinese Academy of Sciences and Honorary President of Peking Union Medical College Hospital serving as President of the Chinese Medical Association and Chairman of the Surgical Branch. From 2009 to 2021, in the ranking of China's best specialty reputation published by the Fudan University Hospital Management Institute, the Department of General Surgery ranked first in the country for thirteen consecutive years. Many experts in the department hold important positions such as chairpersons and group leaders in various academic organizations across the country.

The Department of Pancreatic Surgery at Peking Union Medical College Hospital is a core subspecialty group under the Department of General Surgery. Established in 1921, the Department of General Surgery is a key clinical specialty designated by the National Health Commission and has ranked first in the Fudan University's "Comprehensive Ranking of Chinese Hospital Specialties" for 13 consecutive years. The Pancreatic Surgery subspecialty group focuses on three core strengths: early diagnosis and comprehensive treatment of pancreatic cancer, pancreatic neuroendocrine tumors, and robotic and laparoscopic minimally invasive pancreatic surgery. It is one of the earliest established pancreatic disease centers in my country, positioned as the "last line of defense" for the diagnosis and treatment of complex pancreatic diseases nationwide and a "Whampoa Military Academy" for training pancreatic surgical professionals in China.

Historical Origins and Spiritual Inheritance:

In 1951, Professor Zeng Xianjiu performed the first pancreaticoduodenectomy (Whipple procedure) in China at Peking Union Medical College Hospital, pioneering pancreatic surgery in the country. To solve the problem of intraoperative intestinal reflux, Professor Zeng Xianjiu created the "Zeng's Synchronous Semicircular Anastomosis Technique." In the 1970s, Professor Zeng Xianjiu advocated for the establishment of the Peking Union Medical College Hospital Pancreatic Disease Collaborative Group, pioneering the MDT (Multidisciplinary Team) model for complex pancreatic diseases in China. In 2002, under the leadership of Academician Zhao Yuping, the "Peking Union Medical College Hospital Pancreatic Surgery Center" was officially established. The department produced pancreatic surgery masters such as Zeng Xianjiu, Zhu Yu, Zhong Shouxian, Cai Lixing, and Zhao Yuping, forming a scholarly spirit of "diligence, truth-seeking, rigor, and innovation."

Core business operational efficiency:

The Pancreatic Surgery Subgroup is one of the five major subgroups of General Surgery. The department sees over 100,000 outpatients and emergency patients annually and performs over 8,000 surgeries per year, with a minimally invasive abdominal surgery rate exceeding 70% and a minimally invasive pancreatic disease surgery rate reaching 90%. Over the past 30 years, they have treated over 2,000 cases of pancreatic cancer and over 500 cases of pancreatic endocrine tumors (including over 300 insulinomas), making it the subgroup with the largest number of cases in Asia. The General Surgery Subgroup consults with over 5,000 patients from all over China (including some from Europe and the United States).

Discipline Positioning and Benchmarking:

It is the leading unit of the Pancreatic Surgery Group of the Surgical Branch of the Chinese Medical Association, with Academician Zhao Yuping serving as the President of the Chinese Medical Association and Chairman of the Surgical Branch. The department is at the forefront domestically and internationally advanced in areas such as early diagnosis and comprehensive treatment of pancreatic cancer, diagnosis and treatment of pancreatic endocrine tumors, application of minimally invasive techniques for pancreatic diseases, and research on pancreatic disease genes. Nearly 400 robotic pancreatic surgeries have been performed, covering almost all types of pancreatic surgery, reaching world-class standards.

Established in 1921, the Department of Basic Surgery is a key clinical specialty of the National Health Commission and has ranked first in the Fudan University's "China Hospital Specialty Ranking" for 13 consecutive years. The Colorectal Surgery Group focuses on minimally invasive colorectal tumor surgery, with transanal endoscopic surgery (TEM) and sphincter-preserving surgery for low rectal cancer as its signature techniques. It also provides surgical treatment for benign anal diseases (severe mixed hemorrhoids, anal fistulas, etc.) and is positioned as a national center for the diagnosis and treatment of complex colorectal and anorectal diseases and a base for the promotion of minimally invasive anorectal surgery technology.

Historical Origins and Spiritual Inheritance:

Established in 1921, the Department of General Surgery is the same age as Peking Union Medical College Hospital and is one of the birthplaces of modern general surgery in China. Professor Zeng Xianjiu served as the head of the Department of Surgery for many years starting in 1956 and was hailed by international surgical colleagues as "a guiding light in the world of surgery." In the early 1980s, Professor Zeng Xianjiu was among the first in China to establish specialized groups for gastrointestinal and pancreatic diseases, laying the foundation for the subspecialty structure. The colorectal specialty group has been gradually improved under the leadership of Professor Qiu Huizhong and Professor Xiao Yi. Professor Qiu Huizhong graduated from Shanghai First Medical College in 1976. Since the 1990s, he has shifted his work and research focus to colorectal and anorectal diseases. He was the first in China to develop TEM technology and promote its standardized application. He currently serves as the vice chairman of the Gastroenterology Committee of the Beijing Anti-Cancer Association, a standing committee member of the Anorectal Committee of the Chinese Medical Association, and the president of the Colorectal Disease Specialist Branch of the Beijing Medical Association.

Core business operational efficiency:

The Department of General Surgery comprises four wards, one laboratory, and two affiliated medical wards. It sees over 100,000 outpatients and emergency patients annually and performs over 8,000 surgeries per year, with level IV surgeries consistently accounting for around 80%. The Colorectal Surgery team performs nearly 1,000 surgeries annually, admitting over 800 cases of colorectal cancer each year, accounting for approximately 90% of the team's surgeries. Previously, the team primarily treated elderly patients with mid-to-low rectal cancer and underlying cardiovascular, cerebrovascular, or pulmonary diseases. These surgeries involved bowel resection, lymph node dissection, and digestive tract reconstruction, often classified as level III or IV high-difficulty surgeries. In 2026, the team innovatively developed laparoscopic radical resection of colorectal cancer as a day surgery, with only a few tiny puncture holes in the patient's abdomen, allowing for discharge within 24 hours and achieving minimally invasive tumor resection surgery.

Discipline Positioning and Benchmarking:

It is a member unit of the Colorectal Surgery Group of the Surgical Branch of the Chinese Medical Association, the deputy leader unit of the TEM Group of the Colorectal Cancer Professional Committee of the Chinese Anti-Cancer Association, and the deputy leader unit of the Colorectal Group of the Surgical Branch of the Beijing Medical Association. Professor Xiao Yi serves as the leader of the Colorectal Surgery Group and an editorial board member of the *Chinese Journal of Surgery*. The group pioneered TEM treatment in mainland China, using it to treat over 500 cases of benign and malignant rectal lesions since 2006. Clinical practice has proven that TEM treatment is safe and effective for localized rectal tumors suitable for local resection. In the Fudan University specialty rankings, its basic surgery department has ranked first in the country for 13 consecutive years.

3353986

It is a national key discipline and a national key clinical specialty; the birthplace of modern internal medicine in China; a national referral center for complex and multi-system diseases in internal medicine, fever of unknown origin, and rare and critical internal medicine cases; it has 12 subspecialties: cardiology, respiratory medicine, gastroenterology, nephrology, hematology, rheumatology and immunology, infectious diseases, general internal medicine, oncology, geriatrics, endocrinology, and MICU; 9 subspecialties consistently rank among the top ten in the national Fudan University specialty reputation list; it inherits the internal medicine grand rounds system and multidisciplinary team (MDT) collaborative diagnosis and treatment; and it is benchmarked against the Department of Internal Medicine at Johns Hopkins University School of Medicine.

Historical Origins and Spiritual Inheritance:

The Department of Internal Medicine at Peking Union Medical College Hospital was established at the hospital's founding in 1921, making it the birthplace of modern internal medicine in China. Its first head, Franklin C. McLean, also served as the president of Peking Union Medical College. After Professor Zhang Xiaoqian returned to Peking Union to lead the department, he established the academic tradition of "patient-centered care, fundamental principles, and rigorous standards." The department consistently adheres to four core medical systems: the resident physician rotation system (5 years, including 1 year as a chief resident), the three-tiered physician ward round system, the internal medicine grand round system, and the chief resident system. The internal medicine grand round system, which has continued since the hospital's founding, aims to "gather wisdom and cultivate talent." Professor Zhang Xiaoqian once said, "You have no right to deprive general practitioners of the opportunity to learn and improve," making it a symbolic embodiment of Peking Union's academic spirit.

Core business operational efficiency:

The Department of Internal Medicine has grown over a century, from its initial few dozen students and five specialties to over 800 students and 12 specialties, covering cardiology, respiratory medicine, gastroenterology, nephrology, hematology, rheumatology and immunology, infectious diseases, general internal medicine, oncology, geriatrics, endocrinology, and MICU. In Fudan University's ranking of hospital specialty reputations in China, nine of the Department of Internal Medicine's specialties are ranked among the top ten nationwide, with rheumatology and immunology and critical care medicine ranking first.

Discipline Positioning and Benchmarking:

The Department of Internal Medicine at Peking Union Medical College Hospital is positioned as the "last line of defense" for the diagnosis and treatment of complex and critical internal medicine cases in China, and as a "Whampoa Military Academy" for cultivating elite medical talent. Benchmarking against world-class internal medicine departments, it possesses unique institutional advantages in areas such as multidisciplinary integrated diagnosis and treatment, long-term residency training, and clinical thinking training through grand rounds. The Department of General Internal Medicine (established in 2004) is the first academic general internal medicine department in China, undertaking the function of coordinated diagnosis and treatment of "multi-system damage or comorbidities that are difficult to distinguish from those treated in other specialties."

Chinese Academy of Medical Sciences, is a national-level consultation center for difficult, rare, and multi-system kidney diseases in China.

Historical Origins and Spiritual Inheritance:

In 1979, Professor Bi Zengqi founded the Nephrology Department of the Department of Internal Medicine at Peking Union Medical College Hospital, making it one of the earliest nephrology departments in China. Starting in 1980, the Union Hospital Nephrology Laboratory and Hemodialysis Unit were established. In 1993, the Nephrology Department was renamed the Department of Nephrology and a Blood Purification Center was established. Professor Bi Zengqi pioneered research on artificial kidneys in China, keeping pace with international standards. He was among the first to explore non-dialysis comprehensive treatment for chronic renal failure, and pioneered the use of low-dose subcutaneous injections of erythropoietin to treat renal anemia. He led his team to be among the first in China to perform renal biopsies and was the first to report on IgA nephropathy. In 1980, he co-founded the Nephrology Branch of the Chinese Medical Association with his colleagues, serving as its first secretary and vice chairman for the second, third, and fourth terms. In 2007, he received the Outstanding Contribution Award from the Nephrology Branch of the Chinese Medical Association, and in 2020, he received the Lifetime Achievement Award from the Nephrology Branch of the Chinese Medical Association.

Core business operational efficiency:

The department comprises specialties including glomerular diseases, tubulointerstitial diseases, hypertensive water and salt metabolism, non-dialysis treatment of chronic renal failure, hemodialysis, peritoneal dialysis, and kidney transplantation. It sees nearly 40,000 outpatients annually and has 52 inpatient beds (32 in the East Campus and 20 in the West Campus), with nearly 1,000 inpatients and renal biopsies per year. The blood purification center currently has over 220 maintenance hemodialysis patients, and the number of peritoneal dialysis patients has increased from 80 to 160. The department is a national peritoneal dialysis demonstration center and medical and nursing training base designated by the National Health and Family Planning Commission.

Discipline Positioning and Benchmarking:

This department is a national key clinical specialty and a national key discipline, ranking sixth nationwide and third in North China in the Fudan University Hospital Specialty Reputation Ranking. It undertakes the "13th Five-Year Plan" National Key Research and Development Program's key project in precision medicine research, "Clinical Contingency Study of Rare Diseases," and has jointly launched the "Registration and Clinical Contingency Study of Rare Kidney Diseases" with twelve other centers across the country. In terms of international benchmarking, Professor Chen Limeng serves as the associate editor of the Journal of the American Nephrology Association and received the first prize of the Beijing Science and Technology Progress Award in 2024 and the Chinese Medical Science and Technology Award in 2022.

The Department of Urology at Peking Union Medical College Hospital is one of the birthplaces and academic centers of urology in China, founded by Academician Wu Jieping, known as the "Father of Urology in China," and other senior medical experts. It is a key clinical specialty of the Ministry of Health, with adrenal surgery as its flagship specialty, precision diagnosis and treatment of urinary tract tumors and kidney transplantation as its pillars, and robotic and laparoscopic minimally invasive techniques as its cutting-edge advancements. It is positioned as the "final destination" for the diagnosis and treatment of complex and difficult urinary system diseases nationwide and a national-level base for training senior urologists. It ranks eighth nationwide in the Fudan University edition of the "China Hospital Specialty Reputation Ranking."

Historical Origins and Spiritual Inheritance:

The Department of Urology at Peking Union Medical College Hospital was founded in the 1940s. In the 1950s, senior medical experts such as Yu Songting, Wu Jieping, and Shi Xi'en established its specialized structure. From the 1960s to the 1980s, experts such as Liu Guozhen, Wu Decheng, and Zang Meifu developed it into a nationally renowned urology department. Inspired by the hospital's motto of "rigor, excellence, diligence, and dedication," and through the passing down of knowledge by several generations of discipline leaders including Liu Guozhen, Wu Decheng, Zang Meifu, Li Hanzhong, Ji Zhigang, and Zhang Yushi, the department has formed a complete subspecialty matrix centered on adrenal surgery, minimally invasive urological surgery, kidney transplantation, urogenital tumors, urinary tract stones, and andrology.

Core business operational efficiency:

The department currently has 3 wards with 110 beds (92 general wards and 18 special needs wards). It admits over 4,000 inpatients annually and performs 3,900 surgeries annually, with complex and difficult surgeries accounting for about one-third. The department sees over 120,000 outpatients annually, with 4,500 outpatient surgeries (including cystoscopy). Minimally invasive surgeries account for over 85% of all surgeries, and nearly 200 robotic surgeries are performed annually. The department currently has 35 physicians, 32 nurses, and 3 technicians, including 9 chief physicians, 10 associate chief physicians, 6 doctoral supervisors, and 5 master's supervisors. It has one standing committee member of the Chinese Medical Association Urology Branch, one vice chairman of the Beijing Medical Association Urology Branch, and many staff members hold important positions in national academic societies.

Discipline Positioning and Benchmarking:

It is a key clinical specialty of the Ministry of Health, a standardized training base for resident physicians in Beijing, and a postdoctoral research station. It is one of the earliest doctoral degree granting units in urology authorized by the State Council Academic Degrees Committee in China. Professor Ji Zhigang serves as a standing committee member of the Urology Branch of the Chinese Medical Association, deputy leader of the Oncology Group of the Urology Branch of the Chinese Medical Association, and vice president of the Urology Branch of the Chinese Medical Doctor Association. He previously served as director of the Department of Urology at Peking Union Medical College Hospital (2014-2023) and has profound expertise in robot-assisted laparoscopic minimally invasive surgery and its domestic research and development. The department has won the third prize of the Chinese Medical Award in the field of diagnostic and treatment standards for adrenal surgical diseases, and its human/kidney survival rate in the field of kidney transplantation is among the most advanced in the country.

The Department of Nuclear Medicine at Peking Union Medical College Hospital is one of the birthplaces of nuclear medicine in China and the location of the National Center for Professional Medical Quality Control in Nuclear Medicine. In the field of 177Lu-PSMA radioligand therapy, the department adheres to the core concept of integrated diagnosis and treatment (Theranostics), with its hallmark strengths in PSMA PET/CT precision screening, 177Lu-PSMA-617 targeted therapy, and EB-PSMA innovative drug development. It is positioned as a national leader in the technology and a standardized promotion center for prostate cancer radionuclide therapy, and has consistently ranked first in the national nuclear medicine specialty rankings in the Fudan University's China Hospital Specialty Reputation Rankings for many years.

Historical Origins and Spiritual Inheritance:

The Department of Nuclear Medicine at Peking Union Medical College Hospital was established in 1958, making it one of the earliest clinical nuclear medicine departments in my country. In 1980, Professor Wang Shizhen was elected as an academician of the Chinese Academy of Sciences. In 1981, it became the first institution in China authorized to grant doctoral degrees in nuclear medicine, and spearheaded the establishment of the Nuclear Medicine Branch of the Chinese Medical Association and the *Chinese Journal of Nuclear Medicine*. Academician Wang Shizhen and other predecessors laid the foundation for the introduction, birth, development, and growth of nuclear medicine, and the history of the Department of Nuclear Medicine at Peking Union Medical College Hospital is considered a "microcosm of the history of nuclear medicine development in China."

Core business operational efficiency:

The department performs over 30,000 routine high-quality imaging examinations and treats over 500 patients annually. It has 2 PET/MR machines, 7 PET/CT machines, and 8 SPECT/CT machines. Its radiopharmaceutical manufacturing equipment includes 2 cyclotrons and 16 positron-emitting drug synthesis hot chambers, and it has a 10-bed radionuclide therapy ward. It offers over 80 routine diagnostic and treatment programs, making it one of the departments in China with the most comprehensive and numerous routine nuclear medicine diagnostic and treatment programs.

Discipline Positioning and Benchmarking:

Designated a National Key Clinical Specialty by the National Health Commission and a Beijing Key Laboratory for Molecular Targeted Diagnosis and Treatment in Nuclear Medicine, the facility was approved in 2020 to establish the National Center for Medical Quality Control in Nuclear Medicine. Since nuclear medicine was included in the Fudan University's ranking of Chinese hospital specialties in 2014, it has consistently ranked first nationwide for many years. Internationally, in 2025, it will host regional training courses for the International Atomic Energy Agency (IAEA), providing training for 28 professionals from 18 countries.

One of the earliest established respiratory specialties in the country, and a national-level guidance center for the diagnosis and treatment of complex and critical respiratory diseases; relying on the hospital's MDT platform, it focuses on interstitial lung disease, pulmonary vascular disease, rare lung diseases, complex lung infections, lung cancer, and sleep apnea, while also taking into account common airway diseases and respiratory critical care. It accepts complex respiratory cases with unclear diagnoses that have been referred from all over the country, and undertakes the formulation of domestic respiratory disease standards, talent training, and clinical translational research.

Historical Origins and Spiritual Inheritance:

In 1930, Professor Qiu Zuyuan opened a tuberculosis prevention clinic in Dongdan. In 1940, Professor Wang Shuxian was in charge of tuberculosis experiments at the Department of Internal Medicine of Peking Union Medical College Hospital. In 1953, the respiratory group was separated from the Department of Internal Medicine, and Professor Zhu Guiqing took charge of its work. In 1959, Professor Zhu Guiqing and Professor Wu Yingkai of Thoracic Surgery co-edited my country's first reference book on respiratory diseases, "Chest Diseases." In 1981, the Department of Respiratory Medicine was formally established, with Professor Zhu Guiqing serving as its first director. The department has produced two recipients of the "Lifetime Achievement Award for Chinese Respiratory Physicians," Professor Luo Weici and Professor Zhu Yuanjue, as well as recipients of the "Chinese Respiratory Physician Award," including Huang Xizhen, Li Longyun, Cai Baiqiang, and Lu Weixuan. Professor Zhu Yuanjue is the founder and pioneer of the field of interstitial lung disease.

Core business operational efficiency:

The department currently has 33 physicians, including 10 chief physicians, 10 associate chief physicians, and 13 attending physicians. It boasts a comprehensive range of subspecialties, covering 11 groups: Chronic Obstructive Pulmonary Disease (COPD), Sleep-Disordered Breathing, Interstitial Lung Disease, Lung Cancer Center, Pulmonary Embolism and Pulmonary Vascular Disease, Asthma, Critical Care Medicine, Infectious Diseases, Interventional Therapy, Respiratory Therapy, and Smoking Cessation. The department sees over 150,000 outpatients annually, with complex cases accounting for 40%. It hosts several national academic events annually, including the "Peking Union Medical College Hospital Respiratory Diseases Summit."

Discipline Positioning and Benchmarking:

It is a national guidance center for the diagnosis and treatment of complex respiratory diseases, a doctoral training center for respiratory medicine, and a postdoctoral research station. The interstitial lung disease group is led by Professor Xu Zuojun, who serves as the deputy head of the interstitial lung disease group of the Chinese Medical Association's Respiratory Disease Branch and is the chief expert for the Ministry of Science and Technology's "Precision Medicine Research" project on interstitial lung disease. The lung cancer center is led by Professor Wang Mengzhao and Professor Zhang Li. Professor Wang Mengzhao's team led the "Wukong 6" research project, a Chinese-registered study, whose results were published in *The Lancet Respiratory Medicine*. The sleep apnea center is led by Professor Xiao Yi, who established the first sleep apnea treatment center in China (1982) and spearheaded the development of the *Guidelines for the Diagnosis and Treatment of Obstructive Sleep Apnea in Adults (2025)*. Led by Professor Shi Juhong and Professor Xu Kaifeng, the Pulmonary Vascular Disease Group conducted the first evaluation of diagnostic methods for diffuse pulmonary diseases in China.

A national key clinical specialty; ranked first in the national reputation rankings for allergy at Fudan University; the birthplace of allergy in China; a member of the World Allergy Organization (WAO); a founding member of the Allergy Branch of the Chinese Medical Association; the only specialty in China with the qualification to independently develop allergen medical preparations; it has established a comprehensive system for precise allergen identification, specific immunotherapy, targeted intervention with biological agents, and multidisciplinary team (MDT) treatment for severe allergic reactions; and it benchmarks itself against the Department of Allergy and Clinical Immunology at Johns Hopkins Hospital in the United States.

Historical Origins and Spiritual Inheritance:

In 1938, Professor Zhang Qingsong, a leading figure in otolaryngology, went to the United States for advanced studies, while also studying allergy. Upon returning to China in 1939, he immediately began preparations to establish the country's first allergy clinic, but this was interrupted by the war. After the founding of the People's Republic of China, Professor Zhang Qingsong, along with Professor Ye Shitai, restarted the establishment work under conditions of material scarcity. On May 1, 1956, China's first allergy department was officially established at Peking Union Medical College Hospital, marking the birth of clinical allergy in China. In the early 1960s, Professor Ye Shitai confirmed that Artemisia species were the most important seasonal allergen in northern China, laying the foundation for hay fever research in China. The department was the first in the world to report that Artemisia pollen and Hops pollen are the main allergens causing hay fever in northern China during summer and autumn. It was also the first in China to conduct research on hereditary angioneurotic edema and the diagnosis and treatment of allergic diseases in infants and young children. The department diagnosed the first case of allergic bronchopulmonary aspergillosis and the first case of wheat-dependent exercise-induced anaphylactic shock in China.

Core business operational efficiency:

The department sees 120,000 outpatients annually, with patients coming from all over the country. It houses the "Allergen Medical Institution Preparation Room" (the only allergen medical institution preparation unit approved by the National Medical Products Administration), which has developed over 200 kinds of crude allergen products with Chinese characteristics. For decades, these products have supported the development of allergy treatment in China, benefiting over ten million people. In 2014, nine allergen injectable preparations received approval numbers from the National Medical Products Administration, allowing them to be dispensed to other hospitals under the supervision of the drug regulatory authorities. In the past five years, he has undertaken 16 National Natural Science Foundation of China projects and 9 provincial and ministerial-level projects, presided over the formulation of 21 clinical diagnosis and treatment guidelines for allergic diseases, published more than 200 SCI papers, and obtained 8 national invention patents.

Discipline Positioning and Benchmarking:

The birthplace and cradle of clinical allergy in China, the National Center for the Diagnosis and Treatment of Difficult and Complex Allergic Diseases, one of the first batch of key clinical specialty construction units for allergy in China, and a clinical research base for allergic drugs of the State Food and Drug Administration. It is a council member of the WAO (World Allergy Organization), a standing council member of the Asia-Pacific Allergy Organization, a founding unit of the Allergy Branch of the Chinese Medical Association, a founding unit and president unit of the Allergy Physicians Branch of the Chinese Medical Doctor Association, and the editor-in-chief unit of the *Chinese Journal of Clinical Immunology and Allergy*. It has consistently ranked first in the allergy specialty in the Fudan University version of the China Hospital Specialty Reputation Ranking for many years, and ranks first in the allergy specialty in the *China Hospital Science and Technology Influence Ranking*. In 2025, the EAACI Hong Kong Allergy Institute announced that the next EAACI Allergy Institute will be held in Beijing in May 2026, co-hosted by EAACI and the Department of Allergy and Respiratory Medicine, marking a substantial improvement in the discipline's international academic discourse power.

A national key clinical specialty. Its core specialties include the diagnosis and treatment of fever of unknown origin, comprehensive diagnosis and treatment of HIV/AIDS, treatment of complex and critical infections, and infection control in immunocompromised populations. It is positioned as the "last line of defense" for the diagnosis and treatment of complex infectious diseases nationwide and a training base for advanced infectious disease professionals. Since 2018, it has consistently ranked third nationwide in the Fudan University Hospital Management Institute's Best Specialty Reputation Ranking.

Historical Origins and Spiritual Inheritance:

The Department of Infectious Diseases is one of the earliest departments established at Peking Union Medical College Hospital. Successive directors, including Li Bangqi, Wang Aixia, Sheng Ruiyuan, Deng Guohua, and Li Taisheng, have shouldered heavy responsibilities, making the prevention and control of infectious diseases in my country their mission. In 1985, Professor Wang Aixia discovered the first AIDS patient in mainland China. In 1995, she led the development of the first national standard protocol for AIDS diagnosis and treatment and established the first P3 laboratory in a Chinese hospital, thus initiating a systematic approach to AIDS prevention and control in China. In 1999, Professor Li Taisheng returned to China after completing his studies in France, bringing back flow cytometry equipment gifted by his mentor, thus beginning a new journey in the fight against AIDS at Peking Union Medical College Hospital. Under the leadership of two generations of academic leaders, Wang Aixia and Li Taisheng, the department has played a pivotal role in the prevention and control of infectious diseases in my country at various stages of history.

Core business operational efficiency:

The department currently has 38 beds and 39 staff members, including 19 physicians, 7 with senior professional titles, and 7 with associate senior professional titles. It sees approximately 48,000 outpatients annually and admits about 600-800 inpatients annually. Since 2011, it has offered specialized outpatient clinics for febrile diseases, immunodeficiency, and tuberculosis/non-tuberculous mycobacterial infections. Since its establishment, the department has won the first prize for medical achievements from Peking Union Medical College Hospital 10 times and national and provincial/ministerial-level science and technology progress awards 12 times.

Discipline Positioning and Benchmarking:

It is a doctoral degree granting unit for infectious diseases, a key clinical discipline of the Ministry of Health, a national-level clinical trial base for infectious disease drugs, and a national-level training base for AIDS comprehensive prevention and control demonstration zones. The discipline is positioned as an infectious disease department in general hospitals, with core clinical specialties including the diagnosis and treatment of complex and critical infectious diseases, fever of unknown origin, diagnosis and treatment of AIDS and opportunistic infections, rational use of antibiotics and hospital infection control, application of lymphocyte immune subset detection platforms, and diagnosis and treatment of infections in immunocompromised populations. Director Li Taisheng spearheaded the publication of the "Guidelines for the Diagnosis and Treatment of AIDS in China," which has been updated five times to date, and has conducted over 200 lectures nationwide, playing a crucial role in promoting the improvement of comprehensive AIDS diagnosis and treatment standards in my country.

A national key clinical specialty and a key laboratory for rheumatology and immunology of the Ministry of Education; ranked first in the national rheumatology and immunology category in Fudan University's specialty reputation rankings for many consecutive years; the National Clinical Research Center for Skin and Immune Diseases; one of the birthplaces of rheumatology and immunology in China, and hailed as the "Whampoa Military Academy" of Chinese rheumatology; it has established an MDT (Multidisciplinary Team) diagnosis and treatment system for connective tissue diseases, systemic vasculitis, IgG4-related diseases, and difficult autoimmune diseases; and it benchmarks itself against the Department of Rheumatology and Immunology at the Mayo Clinic in the United States.

The birthplace of rheumatology and immunology in China, the National Clinical Research Center for Skin and Immune Diseases, and an Asia-Pacific Rheumatology Alliance (APLAR) Center of Excellence; ranked first in the national rheumatology specialty in Fudan University's specialty reputation list for 15 consecutive years, and a national referral center for difficult and critical rheumatological and immunological diseases in China, benchmarked against top international rheumatology centers (Johns Hopkins Rheumatology and Immunology Center in the United States, and the Royal Institute of Rheumatology in the United Kingdom).

Historical Origins and Spiritual Inheritance:

Founded by Professor Zhang Naizheng, the "Father of Chinese Rheumatology," the Rheumatology and Immunology Group was established in 1979 and formally established as a department in 1980. Inheriting the spirit of "rigor, precision, diligence, and dedication" of Xiehe University, generations of scholars have laid the foundation for the clinical, testing, and research system of rheumatology and immunology in China. They also established the first autoantibody detection system in China and pioneered the Chinese rheumatology specialty system, earning it the reputation as the "Whampoa Military Academy" of Chinese rheumatology.

Core business operational efficiency:

With 68 open beds, the hospital sees over 150,000 outpatients annually, more than 60% of whom are referred from other regions for complex cases; it admits over 1,200 inpatients annually; it offers specialized multidisciplinary team (MDT) outpatient services for systemic lupus erythematosus, IgG4-related diseases, Behcet's disease, inflammatory myopathy, vasculitis, and pulmonary hypertension; it leads the National Rheumatology Data Center (CRDC) and the CSTAR Lupus Center, covering over 800 collaborative centers nationwide, and has established a national alliance of medical consortia for rheumatology and immunology. **Core Strengths**: Specializes in treating multi-system involvement, diseases with unclear diagnoses from other hospitals, refractory and recurrent diseases, and critical rheumatic immune diseases; possesses an independent autoimmune laboratory with complete autoantibody profiles, immune function, and biomarker detection capabilities; leverages the hospital-wide MDT platform to collaborate with cardiology, respiratory medicine, nephrology, hematology, and pathology departments to manage multi-organ immune damage; and has access to a national-level drug clinical trial platform.

Discipline Positioning and Global Benchmarking:

A national-level center for the diagnosis, treatment, research, translation, and quality control of complex and critical rheumatic and immune diseases; an Asia-Pacific Rheumatology Alliance Center of Excellence; benchmarking against the Johns Hopkins Rheumatology Center, but differentiating itself from overseas centers that focus on basic research, it coordinates and emphasizes large-sample clinical trials in the Chinese population, multidisciplinary teams (MDTs) for complex multisystem immune diseases, and the development of local treatment guidelines, exporting the "Chinese solution" for rheumatic and immune diseases.

It is a national key discipline, a national key clinical specialty, and a key laboratory of endocrinology of the Ministry of Health; ranked second in the national reputation list of endocrinology at Fudan University; the first endocrinology specialty in China; a national referral center for difficult endocrine and metabolic diseases in China; it has established an MDT diagnosis and treatment system for pituitary, adrenal, bone metabolism, gonads, thyroid, diabetes, and hereditary endocrine rare diseases; and it is benchmarked against the Department of Endocrinology at the Mayo Clinic in the United States.

China's first endocrinology specialty, a national key clinical specialty, and the affiliated unit of the National Health Commission's key laboratory for endocrinology; ranked first in the Fudan University Specialty Reputation Ranking and Hospital Science and Technology Evaluation (STEM) Endocrinology and Metabolism Specialty for many consecutive years; a national referral center for difficult and rare endocrine and metabolic diseases in China; benchmarked against top international endocrinology centers (Department of Endocrinology, Massachusetts General Hospital, USA; Cambridge Metabolism and Endocrinology Centre, UK).

Historical Origins and Spiritual Inheritance:

In 1925, the Department of Internal Medicine at Peking Union Medical College established a metabolic ward to begin endocrine and metabolic research. In 1958, Professors Liu Shih-hao and Zhu Hsien-yi formally established the first endocrinology specialty in China, which was further developed by generations of experts, including Academician Shi Yi-fan. Inheriting the spirit of "rigor, excellence, diligence, and dedication" of Peking Union Medical College, the department practices the "clinical-laboratory-clinical" translational medicine paradigm. In 1942, Liu Shih-hao and Zhu Hsien-yi named CKD-MBD, which was the first disease named by Chinese people and included in international medical literature.

Core business operational efficiency:

With 66 beds, the hospital sees nearly 200,000 outpatients annually, over 60% of whom are referred from other regions for complex cases. It admits more than 1,500 inpatients annually. The hospital has established four multidisciplinary team (MDT) centers for pituitary diseases, metabolic bone diseases, diabetes, and obesity. It collaborates with departments such as neurosurgery, urology, nuclear medicine, pathology, and imaging to conduct multidisciplinary consultations. The hospital has also established a biobank and clinical queue for endocrine diseases in the Chinese population, and undertakes referrals of complex endocrine cases from across the country.

Core strengths:

Specializing in cases with insidious etiologies, repeated misdiagnoses in other hospitals, rare genetic endocrine diseases, and refractory endocrine tumors; possessing a key endocrine laboratory designated by the National Health Commission, with a complete set of hormone function tests and endocrine molecular genetic testing systems; employing a routine MDT mechanism to address cross-organ endocrine tumors and complex bone metabolic diseases; and having a leading domestic clinical trial platform for innovative endocrine drugs.

Discipline Positioning and Global Benchmarking:

A national-level center for the diagnosis, treatment, research, translation, and guideline development of rare and complex endocrine and metabolic diseases; benchmarked against the Massachusetts General Hospital Endocrinology Center; differentiating itself from overseas centers by focusing on basic mechanism research, while coordinating and highlighting the profiling of endocrine diseases in the Chinese population, precise localization of occult endocrine tumors, and clinical diagnosis and treatment of rare hereditary endocrine diseases, and exporting Chinese treatment protocols for endocrine and metabolic diseases.

A National Key Clinical Specialty. With Comprehensive Geriatric Assessment (CGA) as its core technology and frailty-sarcopenia intelligent assessment and intervention as its hallmark strength, it has constructed a comprehensive service model encompassing "whole person, whole process, whole family, whole team, and whole community," positioning itself as a leader in geriatric medicine nationwide and a model center for age-friendly healthcare. For many consecutive years, it has ranked eighth nationally and among the top three in North China in the Fudan University's ranking of Chinese hospital specialty reputations.

Historical Origins and Spiritual Inheritance:

In 2007, with the support of the Chinese Medical Foundation (CMB), Peking Union Medical College Hospital collaborated with the Department of Geriatrics at Johns Hopkins University School of Medicine to launch a geriatric medicine project, aiming to introduce and localize modern geriatric medicine concepts. A "Demonstration Ward for Geriatrics" was established in May 2007, became an independent specialty group under the Department of Internal Medicine in 2010, and was officially renamed the "Department of Geriatrics" in 2016. Eighteen medical and nursing staff members have been sent to the Johns Hopkins University Center for Geriatrics for further training, covering internal medicine, neurology, medical psychology, nutrition, and nursing, forming an interdisciplinary team with rich clinical and nursing knowledge. The department's core philosophy is "patient-centered," with the goal not to cure a single disease, but to maintain the functional status of the elderly, support home-based aging, and improve the quality of life for the elderly and their families.

Core business operational efficiency:

The department currently has 24 beds and implements a three-tiered ward round system with attending physicians in charge. The ward primarily focuses on the treatment and some rehabilitation of elderly patients in the subacute phase. There are currently 7 staff members, including chief physicians, associate chief physicians, and attending physicians. All doctors have over 7 years of clinical experience and have completed rotations in various internal medicine specialties and emergency departments. The annual outpatient volume has been steadily increasing. Since 2014, the department has successively opened specialized outpatient clinics such as frailty-sarcopenia clinic, geriatric memory clinic, comprehensive geriatric outpatient clinic, palliative care clinic, and multidisciplinary team (MDT) geriatric medicine clinic. It has also established an online assessment platform, "He Nian Geriatric Management." In 2026, in collaboration with the Department of Stomatology, we launched the "Geriatric-Stomatological Joint Outpatient Clinic" to address the pain points of elderly patients who face "difficulty in accessing dental care and high risks."

Discipline Positioning and Benchmarking:

Since 2010, CGA (Comprehensive Assessment) has been offered to all elderly inpatients, making it one of the earliest institutions in China to implement CGA, forming a GEM (Geriatric Empowerment) ward model with comprehensive assessment and holistic individualized intervention. Modular assessments are used in outpatient clinics to improve efficiency, and functional and palliative care-related assessments are strengthened in continuous care both within and outside the hospital. Internationally, the institution maintains close cooperation with geriatric medicine experts from Johns Hopkins University Geriatrics Center in the United States, Canada, France, and other countries, and has hosted the "Peking Union Medical College-Johns Hopkins Geriatrics Forum" for many consecutive years, which has become one of the most influential academic exchange platforms in the field of geriatrics in China. The 2025 forum, themed "Innovation, Integration, and Development: Advances in Geriatric Medicine in the Context of Global Aging," had nearly a thousand participants both online and offline.

A national key clinical specialty; ranked No. 1 in the national general surgery category in Fudan University's specialty reputation list for many consecutive years; the birthplace of modern pancreatic surgery, surgical enteral and parenteral nutrition in China; a national referral center for complex and critical cases in general surgery; comprising subspecialties in pancreatic surgery, gastrointestinal surgery, hepatobiliary surgery, thyroid and parathyroid surgery, colorectal surgery, hernia and abdominal wall surgery, and surgical nutrition; pioneered the MDT diagnosis and treatment model for pancreatic diseases in China; benchmarked against the Department of General Surgery at Massachusetts General Hospital in the United States.

Historical Origins and Spiritual Inheritance:

Established in 1921, the Department of General Surgery is the same age as Peking Union Medical College Hospital and is one of the birthplaces of modern general surgery in China. Renowned medical figures such as Zeng Xianjiu, Zhu Yu, Fei Limin, Jiang Zhuming, and Zhong Shouxian laid the foundation for the discipline here. In the early 1980s, Professor Zeng Xianjiu was among the first in China to establish specialized groups for pancreas, gastrointestinal, breast, hepatobiliary, surgical nutrition, and critical care, laying the foundation for the subspecialty structure of Peking Union Medical College Hospital's general surgery department. In 1951, Professor Zeng Xianjiu performed my country's first pancreaticoduodenectomy, pioneering pancreatic surgery in China. Professors Zhu Yu, Zhao Yuping, and Qiu Huizhong, among others, gradually improved the subspecialty system, and in 2012 it became a national key clinical specialty.

Core business operational efficiency:

The hospital admits over 30,000 inpatients and sees over 300,000 outpatients annually, performing nearly 16,000 surgeries. Level IV surgeries have consistently accounted for around 80% of all surgeries, and the proportion of complex and difficult surgeries ranks among the highest in the country. From 2009 to 2021, it has been ranked first in the Basic Surgery category of the Fudan University's Best Specialty Reputation Ranking in China for thirteen consecutive years.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty and a key discipline in Beijing, and the president unit of the Chinese Medical Association and the chairman unit of its surgical branch. Positioned as a national center for the diagnosis and treatment of complex and critical diseases in general surgery, it has pancreatic surgery as its flagship specialty, achieving internationally advanced levels in early diagnosis, comprehensive treatment, and minimally invasive techniques for pancreatic cancer.

The Department of Breast Surgery at Peking Union Medical College Hospital is one of the earliest established breast specialty departments in China, ranking first nationwide in the Fudan University's "China Hospital Specialty Reputation Ranking." The department focuses on early diagnosis and precise surgical treatment of breast cancer, with its hallmark strengths in areareolar incision breast-conserving surgery, the AI-IRT preclinical screening system for breast cancer, and surgical treatment of refractory plasmacytic mastitis/granulomatous lobular hyperplasia. It is positioned as a national center for the diagnosis and treatment of complex breast diseases and a leading unit in the formulation of China's breast cancer screening standards.

Historical Origins and Spiritual Inheritance:

The Breast Surgery Group at Peking Union Medical College Hospital was established in the 1980s with the proposal and support of Professor Zeng Xianjiu, one of the founders of surgery in my country, and Professor Huang Hanyuan served as the group leader. In February 2006, the Breast Surgery Group expanded into the independent Department of Breast Surgery at Peking Union Medical College Hospital, with Professor Sun Qiang as director. Professor Huang Hanyuan specializes in refractory breast diseases such as plasmacytosis and granulomatous lobular hyperplasia, and has creatively integrated breast flap transfer technology with lesion removal surgery, solving a major recognized challenge in the field of breast surgery worldwide. In 2009, the department established the "Peking Union Pink Garden" public welfare organization, organically combining comprehensive breast cancer management with humanistic care.

Core business operational efficiency:

The Department of Breast Surgery currently has 39 inpatient beds, treating over 90,000 patients annually and performing over 4,500 surgeries annually, including over 2,200 breast cancer surgeries. The department undertakes several national key research projects, including the National Eleventh Five-Year Plan project "Comparison and Evaluation of Community-Based Breast Cancer Screening Programs," the Twelfth Five-Year Plan project "Establishing a Breast Cancer Screening Model Suitable for China's National Conditions," and the Beijing Municipal Science and Technology Commission's major project "Establishment of Technical Solutions and Standardized Diagnostic Procedures for Breast Cancer Screening." For many consecutive years, the department has maintained the lowest single-disease fee for breast cancer in Beijing.

Discipline Positioning and Benchmarking:

It is the vice-chairman unit of the Beijing Breast Disease Prevention and Treatment Association and the chairman unit of the Breast Cancer Professional Committee of the Chinese Research Hospital Association. Professor Sun Qiang led the formulation of the "Guidelines for Breast Cancer Screening in Chinese Women (2022 Edition)," which clearly recommends breast ultrasound as the preferred screening method for breast cancer in Chinese women. The discipline is benchmarked against world-class breast cancer centers, and its comprehensive strength ranks among the advanced ranks in the country.

The Thyroid Specialty Group is a core subspecialty under the Department of General Surgery. Established in 1921, the same year as Peking Union Medical College Hospital, the Department of General Surgery has been ranked first in the Fudan University's "China Hospital Specialty Ranking" for thirteen consecutive years. It is a key clinical specialty of the National Health Commission and a national center for the diagnosis and treatment of complex and critical diseases in general surgery. The Thyroid Specialty Group focuses on standardized surgical treatment of thyroid cancer, with its signature technological advantages being the preservation of recurrent laryngeal nerve and parathyroid function, scarless cervical laparoscopy, and robotic cosmetic surgery. It holds a leading position in China in the standardized diagnosis and treatment of papillary thyroid carcinoma and follicular thyroid carcinoma, as well as the comprehensive diagnosis and treatment of medullary carcinoma, undifferentiated carcinoma, and other rare cancers.

Historical Origins and Spiritual Inheritance:

As early as the 1980s, the Department of General Surgery was among the first in China to refine and subdivide into subspecialty groups, laying the foundation for the in-depth development of various subspecialties, including the thyroid. Through the passing down of knowledge by generations of renowned surgeons such as Zeng Xianjiu, Zhu Yu, Fei Limin, and Zhao Yuping, the thyroid specialty group has gradually grown and developed under the leadership of senior experts like Professor Gao Weisheng and Professor Liu Yuewu. In recent years, Professor Li Xiaoyi has served as the Vice Chairman of the CSCO Thyroid Cancer Expert Committee, participating in the compilation of several national guidelines for the diagnosis and treatment of thyroid cancer. He has actively promoted standardized treatment models such as proactive monitoring of low-risk thyroid microcarcinomas and multidisciplinary team (MDT) approaches for advanced thyroid cancer, leading the specialty group in continuous and in-depth research in the surgical and comprehensive treatment of thyroid diseases. The professional group's motto is "diligence, truth-seeking, rigor, and innovation," carrying on the century-old spirit of the Collaborative Association.

Core business operational efficiency:

The Department of General Surgery currently has 4 wards, 1 laboratory, and 2 affiliated wards. It sees over 100,000 outpatients and emergency patients annually and performs over 8,000 surgeries per year, with level IV surgeries consistently accounting for around 80%. The Thyroid Specialty Group is one of the subspecialties with the highest surgical volume in General Surgery, performing over 1,000 thyroid surgeries annually. The group's core physicians each perform between 300 and 500 thyroid surgeries annually. Professor Liu Yuewu, in particular, performs approximately 500 thyroid surgeries annually, possessing extensive surgical experience, and has had no complaints of recurrent laryngeal nerve injury to date. The department undertakes key medical tasks such as healthcare for senior officials and medical treatment for foreign guests. Thanks to the comprehensive diagnosis and treatment platform of Xiehe Hospital, the incidence of complications after thyroid surgery remains at an extremely low level.

Discipline Positioning and Benchmarking:

It is the vice-chair unit of the Thyroid and Metabolism Group of the Surgical Branch of the Chinese Medical Association, and the chairman unit of the Parathyroid and Bone Metabolism Professional Committee of the Chinese Research Hospital Association. The professional group holds a leading position in the field of endocrine surgery nationwide and has participated in the formulation of several national-level diagnosis and treatment guidelines, such as the "Chinese Expert Consensus on Laparoscopic and Robotic Parathyroid Surgery (2024 Edition)" and the "Expert Consensus on Postoperative Hypoparathyroidism Management". In the development of thyroid cancer treatment guidelines, Professor Li Xiaoyi participated in the compilation of the Guidelines for the Diagnosis and Treatment of Continuous/Recurrent and Metastatic Thyroid Cancer (Chinese and English versions), the CSCO Guidelines for the Diagnosis and Treatment of Differentiated Thyroid Cancer (2021), and the CSCO Guidelines for the Diagnosis and Treatment of Medullary Thyroid Carcinoma (2022), fully demonstrating the discipline's academic influence in the field of thyroid surgery nationwide. Internationally, key members of the professional team serve as members of the American Thyroid Association (ATA) and maintain academic exchanges with top international thyroid centers such as the Mayo Clinic and UCLA.

The Department of Hepatobiliary Surgery at Peking Union Medical College Hospital is one of the earliest departments in China to perform liver resection surgery and is a national key clinical specialty. Its core strengths lie in the comprehensive treatment of complex hepatobiliary tumors, immunomodulatory transformation surgery, liver transplantation, and three-dimensional liver function assessment. Positioned as a national center for the diagnosis and treatment of complex hepatobiliary diseases, it has consistently ranked first in the Fudan University's ranking of Chinese hospital specialty reputations for many years.

Historical Origins and Spiritual Inheritance:

Under the leadership and efforts of senior surgeons such as Professor Zeng Xianjiu and Professor Zhong Shouxian, the Department of Surgery at Peking Union Medical College Hospital began performing liver surgery as early as the 1950s, making it one of the earliest hospitals in China to perform liver resection. Later, it developed from the basic surgical liver specialty group into a liver surgery center, and finally into an independent liver surgery department, undergoing more than half a century of growth. Professor Zhong Shouxian, under the guidance of Director Zeng Xianjiu, established one of the earliest pancreatic surgery departments in China at Peking Union Medical College Hospital. Under Zeng's direct leadership, the hospital performed its first liver transplant, laying a solid foundation for the department's hepatobiliary and pancreatic surgery. Professor Huang Jiefu, former Vice Minister of Health, is the honorary director of the department. He is recognized as the promoter and academic leader of the second wave of liver transplantation in China in the mid-1990s. He serves as the chairman of the National Organ Transplantation Committee (OTC) and a lifetime member of the American Liver Transplantation Association. He has won 6 provincial and ministerial-level scientific research awards and has edited 11 surgical monographs.

Core business operational efficiency:

The Department of Hepatobiliary Surgery currently has 28 beds and is located at the East Campus of Peking Union Medical College Hospital. It admits over 1,000 patients annually and performs nearly 500 surgeries, of which approximately 400 are liver surgeries. The department has 4 doctoral supervisors, 3 master's supervisors, 5 full professors, and 5 associate professors, all holding doctoral degrees. Leveraging the hospital's strong comprehensive diagnostic and treatment platform, the complication rate for various hepatobiliary surgeries remains below 2%. The department has successfully diagnosed and treated a variety of complex hepatobiliary diseases, including the world's first case of primary epithelial-myoepithelial carcinoma of the liver.

Discipline Positioning and Benchmarking:

In 2010, the Department of Hepatobiliary Surgery, along with the Department of General Surgery, was selected for the National Health and Family Planning Commission's Key Clinical Specialty Construction Project. In the Fudan University edition of the "China Hospital Specialty Reputation Ranking," the Department of Hepatobiliary Surgery ranked No. 1 nationally and No. 1 in North China. In the past five years, the department has published 60 SCI papers as first or corresponding author, with a total impact factor of nearly 300, applied for 8 patents, and established a biobank for hepatobiliary surgery (containing 1,000 tissue specimens, 10,000 peripheral blood specimens, and a complete follow-up database). In 2006, the department received a grant of one million US dollars from the Chinese Medical Foundation (CMB), jointly undertaken by Peking Union Medical College Hospital, the First Affiliated Hospital of Sun Yat-sen University, and Tianjin First Central Hospital, to assist in establishing domestic transplant standards and registration systems. The department maintains cooperative exchanges with renowned international universities such as Harvard University, the University of Chicago, and UCSF, and has hosted the University of Chicago-Peking Union Medical College Hospital Liver Surgery Joint Conference for many consecutive years.

The Department of Orthopedics at Peking Union Medical College Hospital (a national key discipline and a national key clinical specialty, ranked 5th nationally in the Fudan University Specialty Reputation Ranking for Orthopedics); the hospital's Orthopedic Trauma Center, relying on the Peking Union Medical College Hospital Comprehensive Critical Care Platform, specializes in treating osteoporotic fractures in the elderly, complex pelvic and acetabular fractures, multiple injuries, and old bone injuries; it has established a comprehensive trauma MDT (Multidisciplinary Team) treatment system; and it benchmarks itself against the Department of Trauma Orthopedics at Johns Hopkins Hospital in the United States.

Historical Origins and Spiritual Inheritance:

The Department of Orthopedics at Peking Union Medical College Hospital was founded in the 1920s and is one of the birthplaces of modern orthopedics in China. Its foundation was laid by orthopedic pioneers such as Meng Jimao and Fang Xianzhi. In 2003, a dedicated Trauma Specialty Group was independently established, under the guidance of Academician Qiu Guixing and spearheaded by Professor Zhang Baozhong. The department upholds Peking Union Medical College Hospital's philosophy of prioritizing comprehensive assessment, emphasizing underlying diseases, and reducing the perioperative mortality risk of elderly trauma patients. It goes beyond simple fracture reduction and fixation, emphasizing holistic life support.

Core business operational efficiency:

With over 30 beds; 24-hour orthopedic emergency care; performing hundreds of complex pelvic and hip fractures, intra-articular fractures, hip fractures in the elderly, and multiple trauma surgeries annually; receiving referrals from across the country for complex old fractures, non-healing/malhealing fractures, and fractures in the very elderly complicated with multiple systemic internal diseases; an AO International Trauma Training Base, undertaking standardized training in trauma orthopedics.

Core Advantages: A complete closed-loop treatment system encompassing trauma assessment → MDT consultation for underlying systemic diseases → minimally invasive/open reduction and fixation of fractures → intervention for osteoporosis → long-term postoperative rehabilitation management; distinct from pure trauma centers, specializing in fragility fractures, complex pelvic and acetabular fractures, open fractures with bone defects, and non-union/malunion of fractures in patients over 90 years old with concurrent cardiovascular/nephrological/pulmonary chronic diseases; relying on the hospital's intensive care, anesthesia, and geriatric departments to address trauma patients in other hospitals who cannot undergo surgery due to underlying medical conditions.

Discipline Positioning and Global Benchmarking:

A benchmark for complex geriatric bone trauma in comprehensive hospitals in China; benchmarked against the Department of Traumatic Orthopedics at Johns Hopkins University in the United States; focusing on acute, severe, and multiple traumas, similar to Jishuitan Hospital and Shanghai Sixth People's Hospital's trauma centers; Peking Union Medical College Hospital's Department of Traumatic Orthopedics emphasizes integrated internal medicine and surgical management of fragility fractures, complex pelvic and acetabular fractures, and old traumatic bone diseases in the elderly. Founded in the 1920s, Peking Union Medical College Hospital's Department of Orthopedics is the birthplace of orthopedic medical treatment, teaching, and research in my country. Many orthopedic pioneers, including Meng Jimao, Fang Xianzhi, Wang Guisheng, Feng Chuanhan, Wu Zhikang, Wang Fuquan, and Lu Shibi, have taught and worked here. Professor Wang Guisheng was the first in my country to successfully apply artificial femoral head replacement to treat femoral neck fractures, establishing Peking Union Medical College Hospital's pioneering position in the field of bone and joint trauma. The Trauma Orthopedics Specialty Group established a trauma center in the West Campus in 2003, and moved to the Third Orthopedic Ward in the East Campus in 2013. Under the guidance of Academician Qiu Guixing and Director Weng Xisheng, Professor Zhang Baozhong, as the academic leader, together with Zhang Jia, Gao Peng, Zhang Wanli, and others, has promoted the diagnosis and treatment of bone and joint injuries to a more professional and refined level.

It is affiliated with Peking Union Medical College Hospital Orthopedics (a national key discipline and national key clinical specialty, ranked 5th in the national orthopedics ranking of Fudan University Specialty Reputation); a top-tier spinal deformity diagnosis and treatment center in China; a world-leading team in the field of spinal deformities; it has subgroups for spinal deformities, minimally invasive spinal degeneration, and spinal tumors and infections; it has established an MDT system for complex spinal diseases; and it benchmarks itself against the TSRH Spinal Deformity Center and Johns Hopkins Spine Surgery Center in the United States.

Historical Origins and Spiritual Inheritance:

Founded in the 1920s, the Department of Orthopedics at Peking Union Medical College Hospital is the birthplace of orthopedic medicine, teaching, and research in my country. Many pioneering orthopedic surgeons, including Meng Jimao, Fang Xianzhi, Wang Guisheng, Feng Chuanhan, Wu Zhikang, and Lu Shibi, taught and worked there. In 1982, Professor Wu Zhikang initiated and established the Spinal Surgery Group of the Chinese Medical Association Orthopedics Society, serving as its first leader, thus solidifying Peking Union Medical College Hospital's leading position in spinal surgery nationwide. Under the leadership of Academician Qiu Guixing, the Department of Orthopedics at Peking Union Medical College Hospital has become a National Key Discipline of the Ministry of Education, a Key Clinical Discipline of the Ministry of Health, the Orthopedic Medical Research Center of the Chinese Academy of Medical Sciences, and the Beijing Key Laboratory of Bone Deformity Genetics.

Core business operational efficiency:

The Department of Orthopedics has 132 beds, sees over 150,000 outpatients annually, and performs over 5,000 surgeries annually. The Spinal Surgery Center is a traditional strength of the department, having completed over 2,400 surgeries for spondylolisthesis and established the world's largest database of hemivertebrae resection cases. The department has ranked among the top five in China's hospital specialty reputation rankings for 11 consecutive years.

Discipline Positioning and Benchmarking:

Positioned as a national center for the diagnosis and treatment of spinal deformities and complex spinal diseases, it boasts a landmark advantage in spinal deformity correction. Internationally, Academician Qiu Guixing's team discovered the pathogenic relationship between the TBX6 gene and congenital scoliosis, with their research published in the New England Journal of Medicine, winning the first prize of the Ministry of Education's Natural Science Award. Professor Zhang Jianguo pioneered the "short-segment osteotomy fusion combined with dual growth rod technology" for the treatment of severe early-onset scoliosis, reaching an internationally leading level. In 2024, it led the National Key Research and Development Program "Construction of a Precision Diagnosis and Treatment System for Spinal Deformities and Research on Key Technologies," collaborating with 15 domestic head and neck orthopedic teams to tackle the challenges.

It is affiliated with Peking Union Medical College Hospital Orthopedics (a national key discipline and a national key clinical specialty; ranked 5th nationally in the Fudan University Specialty Reputation Ranking for Orthopedics); a top-tier spinal deformity treatment center in China, and a benchmark team in the international field of spinal deformity; it has sub-specialties in spinal deformity, minimally invasive spinal degeneration, and spinal tumors and infections; it has established an MDT (Multidisciplinary Team) system for the diagnosis and treatment of complex spinal diseases; and it benchmarks itself against the TSRH Spinal Deformity Center and Johns Hopkins Spine Surgery Center in the United States.

Historical Origins and Spiritual Inheritance:

Founded in the 1920s, the Department of Orthopedics at Peking Union Medical College Hospital is the birthplace of orthopedic medicine, teaching, and research in my country. Many pioneering orthopedic surgeons, including Meng Jimao, Fang Xianzhi, Wang Guisheng, Feng Chuanhan, Wu Zhikang, and Lu Shibi, taught and worked there. In 1982, Professor Wu Zhikang initiated and established the Spinal Surgery Group of the Chinese Medical Association Orthopedics Society, serving as its first leader, thus solidifying Peking Union Medical College Hospital's leading position in spinal surgery nationwide. Under the leadership of Academician Qiu Guixing, the Department of Orthopedics at Peking Union Medical College Hospital has now become a National Key Discipline of the Ministry of Education, a Key Clinical Discipline of the Ministry of Health, the Orthopedic Medical Research Center of the Chinese Academy of Medical Sciences, and the Beijing Key Laboratory of Bone Deformity Genetics.

Core business operational efficiency:

The Department of Orthopedics has 132 beds, sees over 150,000 outpatients annually, and performs over 5,000 surgeries annually. The Spinal Surgery Center is a traditional strength of the department, having completed over 2,400 surgeries for spondylolisthesis and established the world's largest database of hemivertebrae resection cases. The department has ranked among the top five in China's hospital specialty reputation rankings for 11 consecutive years.

Discipline Positioning and Benchmarking:

Positioned as a national center for the diagnosis and treatment of spinal deformities and complex spinal diseases, it boasts a landmark advantage in spinal deformity correction. Internationally, Academician Qiu Guixing's team discovered the pathogenic relationship between the TBX6 gene and congenital scoliosis, with their research published in the New England Journal of Medicine, winning the first prize of the Ministry of Education's Natural Science Award. Professor Zhang Jianguo pioneered the "short-segment osteotomy fusion combined with dual growth rod technology" for the treatment of severe early-onset scoliosis, reaching an internationally leading level. In 2024, it led the National Key Research and Development Program "Construction of a Precision Diagnosis and Treatment System for Spinal Deformities and Research on Key Technologies," collaborating with 15 domestic head and neck orthopedic teams to tackle the challenges.

The Bone and Soft Tissue Tumor Specialty Group at Peking Union Medical College Hospital is a subspecialty group under the Department of Orthopedics. Relying on the comprehensive advantages of Peking Union Medical College Hospital as a national guidance center for the diagnosis and treatment of complex and critical illnesses, it focuses on the standardized comprehensive treatment of bone and soft tissue tumors of the spine, pelvis, and limbs. Its landmark technologies include limb-sparing surgery and functional reconstruction, surgical treatment of tumor-associated hypophosphatemic osteomalacia (TIO), and minimally invasive treatment of spinal metastatic cancer. It is positioned as a national MDT (Multidisciplinary Team) diagnosis and treatment center for complex and difficult bone and soft tissue tumors and bone metastatic cancers. The Department of Orthopedics at Peking Union Medical College Hospital ranks fifth in the Fudan University ranking of Chinese hospital specialties. It is a national key discipline of the Ministry of Education and a key laboratory for the study of skeletal deformity genetics in Beijing.

Historical Origins and Spiritual Inheritance:

Founded in 1921 at the hospital's inception, the Department of Orthopedics at Peking Union Medical College Hospital is the birthplace of orthopedic medicine, teaching, and research in my country. Many orthopedic pioneers, including Meng Jimao, Fang Xianzhi, Wang Guisheng, Feng Chuanhan, Wu Zhikang, and Lu Shibi, have taught and worked here. The Bone Tumor Specialty Group is a subspecialty that has gradually developed within the overall framework of orthopedics, operating on the comprehensive platform of more than ten subspecialty groups within the department. In recent years, Professor Liu Yong, as an academic backbone of the Bone Tumor Specialty Group, has focused on the standardized comprehensive treatment of bone tumors for over a decade, leading the group to a leading level of clinical diagnosis and treatment in China. Professor Liu Yong frankly admitted that bone tumor surgery is highly difficult and involves huge amounts of blood loss. "Two or three thousand milliliters of blood loss is normal, and five or six thousand milliliters is not unexpected." The operating room nurses and anesthesiologists sometimes joke that they "don't want to perform surgery with the bone tumor team because it's too torturous." It is this academic spirit of facing challenges head-on that drives the professional team to constantly push the boundaries of technology.

Core business operational efficiency:

The bone tumor specialist group sees an average of 6,000 outpatients and performs over 800 surgeries annually. Leveraging the robust multidisciplinary team (MDT) platform of Peking Union Medical College Hospital, the group has accumulated extensive experience in the diagnosis and treatment of complex and difficult bone and soft tissue tumors, especially bone metastases. The general orthopedics department sees over 150,000 outpatients and performs over 5,000 inpatient surgeries annually, with 132 beds and dedicated wards. The orthopedic emergency department is open 24/7, year-round.

Discipline Positioning and Benchmarking:

The differentiated positioning of the Peking Union Medical College Hospital Bone Oncology Group lies in its multidisciplinary collaborative capabilities—orthopedics, oncology, radiotherapy, pathology, and radiology departments jointly discuss the patient's condition. For diseases involving systemic treatment, such as bone metastases and bone damage from multiple myeloma, patients can complete primary tumor screening and bone lesion management within the same hospital. In the field of surgical treatment of tumor-associated hypophosphatemic osteomalacia (TIO), Peking Union Medical College Hospital is one of the few centers in Taiwan with mature diagnostic and treatment capabilities; total femoral tumor resection and reconstruction techniques are also a specialty of the group. In the area of limb-sparing surgery combined with functional reconstruction, the professional team, together with other departments such as oncology and radiotherapy, developed a new limb-sparing therapy for radical treatment of primary malignant bone tumors around the knee joint, which won the third prize for medical achievements at Peking Union Medical College Hospital.

It is a national key discipline, a national key clinical specialty, a national center for the diagnosis and treatment of complex and severe obstetric and gynecological diseases, and a national clinical medical research center for obstetric and gynecological diseases; it has been ranked No. 1 in the national reputation list of obstetrics and gynecology for many consecutive years; it is a WHO Collaborating Centre for Research in Human Reproduction; it is the birthplace of modern obstetrics and gynecology in China; it has established an MDT diagnosis and treatment system for gynecological oncology, maternal-fetal medicine, gynecological endocrinology and reproduction, and pelvic floor diseases; and it is benchmarked against the Department of Obstetrics and Gynecology at Johns Hopkins Hospital in the United States. The birthplace of modern obstetrics and gynecology in China; a national key clinical specialty, a national center for the diagnosis and treatment of complex and severe obstetric and gynecological diseases, a national clinical medical research center for obstetric and gynecological diseases, and a WHO Collaborating Centre for Research in Human Reproduction; consistently ranked first in the national reputation list for obstetrics and gynecology at Fudan University; a national referral center for complex and critical gynecological tumors, reproductive tract malformations, and complex maternal-fetal diseases; benchmarked against top international obstetrics and gynecology centers (Johns Hopkins Hospital of Gynecology and Gynaecology, and the Royal College of Obstetricians and Gynaecologists, UK).

Historical Origins and Spiritual Inheritance:

Established in 1921 along with the founding of Peking Union Medical College Hospital, with Academician Lin Qiaozhi laying the foundation; Academician Song Hongzhao overcame the difficult problem of radical cure of velvet carcinoma, and Academician Lang Jinghe devoted himself to gynecological tumors, pelvic floor and endometriosis; inheriting the Peking Union Medical College Hospital spirit of "rigor, pursuit of excellence, diligence and dedication"; forming a "patient-centered" whole life cycle women's health management system, and becoming a cradle of obstetrics and gynecology talents in China.

Core business operational efficiency:

It comprises four subspecialty centers: Obstetrics Center, General Gynecology Center, Gynecologic Oncology Center, and Gynecologic Endocrinology and Reproductive Center; it sees over 200,000 outpatients annually, many of whom are referrals from other hospitals for complex cases; it performs over 10,000 surgeries annually, including numerous level-four high-difficulty surgeries; it offers outpatient services for reproductive tract malformations, endometriosis, pelvic floor disorders, gynecologic tumors, and high-risk pregnancies via multidisciplinary team (MDT); it has established a national collaborative network for obstetrics and gynecology diseases, undertakes remote MDT consultations, and is equipped with a biobank and clinical waiting area.

Core strengths:

Specializing in misdiagnosed, refractory, and rare reproductive tract malformations, complex gynecological malignancies, and high-risk maternal-fetal complications from other hospitals; possessing strong multidisciplinary collaboration capabilities, coordinating with critical care, hematology, rheumatology and immunology, imaging, genetics, and neonatology departments; a national-level new drug clinical trial platform, enabling personalized comprehensive treatment that preserves fertility. Discipline positioning and global benchmarking: a national-level center for the diagnosis, treatment, quality control, guideline development, and translational medicine of complex and critical obstetric and gynecological cases; benchmarking against Johns Hopkins University Obstetrics and Gynecology; differentiating itself from overseas centers that emphasize basic research, while collaborating to highlight the localized diagnosis and treatment system for reproductive tract malformations, pelvic floor diseases, trophoblastic tumors, and high-risk pregnancies in the Chinese population, exporting Chinese obstetric and gynecological treatment protocols.

A national key clinical specialty and discipline, and the birthplace of modern dermatology and venereology in China; it combines standardized diagnosis and treatment of common diseases with a national consultation center for difficult, critical, immune, and rare skin diseases . The history and spirit of Peking Union Medical College Hospital's dermatology department can be traced back to 1869 when John Dudgeon established a dermatology department at Peking Union Medical College Hospital, making it one of the earliest dermatology treatment institutions in China. In 1922, Chester N., an American... Frazier, along with Chen Hongkang and others, co-founded the Department of Dermatology and Syphilis at Peking Union Medical College Hospital, with Fu Ruisi serving as its first director. After the liberation, Li Hongjiong, one of the founders of dermatology and venereology in my country and a first-class professor, served as the department director. In 1962, Professor Li Hongjiong decided to archive pathological slides to establish a pathology database. Since the compilation of the first pathological slide in March 1962, this work has continued to this day. As of June 2021, a total of over 63,600 complete dermatological pathology documents have been compiled and archived, with an average of about 7,000 new specimens added each year. The specimens cover rare skin diseases such as cutaneous lymphoma, melanoma, tumors of skin appendages, and vasculitis. The department has produced four first-class professors: Mu Ruiwu, Hu Chuankui, Qin Zuoliang, and Li Hongjiong, who have made outstanding contributions to the development of dermatology and venereology in China.

Core business operational efficiency:

The dermatology department sees over 500 patients daily from both domestic and international locations, with peak days reaching nearly 1,000 outpatient visits. It has grown into a large dermatology and venereology department with multiple treatment centers specializing in autoimmune cystic disease, psoriasis, sexually transmitted diseases, laser cosmetic treatments, and skin histopathology. In the "China Hospital Specialty Reputation Ranking" published by the Fudan University Hospital Management Institute, the dermatology department ranks among the top in the country; and it has consistently ranked third in the China Hospital Science and Technology Evaluation (STEM) Specialty Ranking for many years.

Discipline Positioning and Benchmarking:

In 2002, it became one of the first batch of national key disciplines, and is a training center for postdoctoral fellows, doctoral students, and master's students, as well as a national clinical pharmacology base. It is the Psoriasis Translational Medicine Research Center of the Chinese Medical Association's Dermatology and Venereology Branch and a national clinical drug research base. Under the leadership of Professor Jin Hongzhong, the department undertakes numerous research projects, including those funded by the National Natural Science Foundation of China, the Ministry of Health's industry-specific funds, and the Beijing Natural Science Foundation. It also leads international collaborative projects such as the Milstein-Asian Medical Foundation Research Fund and the International Union Against Cancer Research Fund. Papers have been published in authoritative international journals such as Science, the New England Journal of Medicine, and the British Journal of Dermatology. At the international level, Professor Jin Hongzhong serves as a council member of the Asian Dermatological Association (ADA), a council member of the Asian Psoriasis Society (ASP), and the chairman of the Rare Skin Diseases Committee of the China Rare Disease Alliance.

A national key clinical specialty; consistently ranked among the top 4 in the Fudan University specialty reputation list nationwide; the birthplace of modern otolaryngology in China; comprising three subspecialties: otology, rhinology, and pharyngology-head and neck surgery; equipped with an artificial cochlea center, a deafness gene laboratory, and an olfactory laboratory; established an MDT (Multidisciplinary Team) diagnosis and treatment system for complex head and neck tumors and congenital ear malformations; benchmarked against the Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery.

Historical Origins and Spiritual Inheritance:

The Department of Otolaryngology at Peking Union Medical College Hospital was founded in 1921, making it one of the birthplaces of modern otolaryngology in China. Professor Liu Ruihua, considered the father of Chinese otolaryngology, joined the hospital in 1919, performed the first mastoidectomy in China in 1928, and became the second department director in 1930. After the founding of the People's Republic of China, Professor Zhang Qingsong spearheaded the establishment of the Otolaryngology Branch of the Chinese Medical Association and the *Chinese Journal of Otolaryngology*, serving as its chairman for the first three terms and as editor-in-chief. During the War of Resistance Against Japan, Lin Bijin, Xu Yinxiang, Hu Maolian, and other otolaryngologists from Peking Union Medical College Hospital went to Tianjin, Chengdu, and other places to establish hospitals and research institutes, spreading the spirit of Peking Union Medical College Hospital throughout the country—Hu Maolian performed the first total laryngectomy in my country amidst the war. From its earliest work in inner ear surgery, transsphenoidal pituitary surgery, and the development of cochlear implants, to its current simultaneous progress in lateral skull base, olfaction, and voice, its century-old heritage has never been interrupted.

Core business operational efficiency:

The department currently has 46 general ward beds and 10 special needs ward beds, and comprises three subspecialties: Otology, Rhinology, and Lung and Head and Neck Surgery. It also houses an Implant Center, a Hearing Aid Center, a Neonatal Hearing Screening and Treatment Center, a Clinical Audiology Laboratory, a Temporal and Skull Base Microsurgery Anatomy and Technique Laboratory, and a Deafness Gene Screening Laboratory. In 2011, it was designated a National Key Clinical Specialty, and from 2011 to 2016, it ranked among the top four in the Fudan University's Best Hospital Specialty Reputation Ranking for four consecutive years. In recent years, the department has undertaken over 30 research projects, including those funded by the Ninth Five-Year Plan, the Twelfth Five-Year Plan, the "973 Program," and the National Natural Science Foundation of China. It has published approximately 150 papers, including over 40 SCI papers, and applied for 26 patents.

Discipline Positioning and Benchmarking:

Positioned as the birthplace of otolaryngology in China and a national center for the diagnosis and treatment of complex ear diseases, the otology group has achieved leading domestic and advanced international standards in the diagnosis and treatment of facial nerve disorders, lateral skull base diseases, and artificial hearing implantation. The current department head, Professor Gao Zhiqiang, serves as the 11th Chairman of the Otolaryngology-Head and Neck Surgery Branch of the Chinese Medical Association. The department continues to deepen its basic research in areas such as facial nerve function testing and objective functional evaluation, deafness genes, and the application of stem cells in the treatment of sensorineural deafness.

A national key clinical specialty; consistently ranked among the top 5 plastic surgery departments in China according to Fudan University's reputation rankings; affiliated with the National Health Commission's Medical Quality Control Center for Plastic and Cosmetic Surgery; one of the earliest established plastic surgery departments in China; subspecialties covering repair and reconstruction, breast augmentation, lymphedema, scar revision, and facial aesthetics; established an MDT (Multidisciplinary Team) diagnosis and treatment system for complex surface deformities and postoperative tumor defects; benchmarked against the Department of Plastic Surgery at Johns Hopkins Hospital in the United States.

Historical Origins and Spiritual Inheritance:

The Department of Plastic and Cosmetic Surgery at Peking Union Medical College Hospital was founded in 1952 by Professor Song Ruyao, one of the founders of plastic surgery in China. In 2003, Professor Qi Keming, then president of Peking Union Medical College Hospital and chairman of the Plastic Surgery Branch of the Chinese Medical Association, led experts such as Qiao Qun, Wang Xiaojun, and Xu Jun to formally re-establish the department as a complete unit. Over the past two decades, it has developed into a comprehensive medical, educational, and research center with leading technology and complete subspecialties. The department is based on the century-old spirit of "serving the people with medicine and pursuing truth in scholarship." In 2025, Professor Qi Keming reviewed the department's development with a presentation titled "A Flourishing Array of Stars—40 Years of Fat Augmentation," emphasizing that "the essence of medicine is to serve life, and technological innovation must always be patient-oriented." In the same year, the department established the Plastic Surgery and Regenerative Medicine Research Center, marking a leap towards an integrated "clinical-scientific research-translational" model.

Core business operational efficiency:

The department currently has 55 medical staff, including 30 physicians (27 of whom hold doctoral degrees), comprising 5 chief physicians and 12 associate chief physicians. The nursing team consists of 25 people, including 2 wound and ostomy specialist nurses, 4 internationally certified lymphedema therapists, and 4 pain relief and swelling reduction patch therapists. It comprises six major treatment units: a general outpatient clinic, the Feng Hui Medical Aesthetics Center, the National Aesthetics Medical Center, general wards, national wards, and day wards. In September 2024, a medical aesthetics department was established at the Macau Medical Centre. The department sees nearly 50,000 outpatients annually and performs over 10,000 surgeries annually. In recent years, he has been approved for more than 20 major projects, including the National Key Research and Development Program and the National Natural Science Foundation of China, published more than 300 SCI and core papers, and edited or translated more than 20 monographs.

Discipline Positioning and Benchmarking:

It is a key specialty of plastic and cosmetic surgery designated by the National Health Commission, the chairman unit of the Plastic Surgery Branch of the Chinese Medical Association, the location of the National Health Commission's Medical Quality Control Center for Plastic and Cosmetic Surgery, and a training base for plastic surgery specialist nurses of the Chinese Nursing Association. Professor Wang Xiaojun, the discipline leader, serves as the director of the National Medical Quality Control Center for Plastic and Cosmetic Surgery and the chairman of the 10th Committee of the Plastic Surgery Branch of the Chinese Medical Association. The department has been ranked among the top 5 in the Fudan University's ranking of Chinese hospital specialty reputations for six consecutive years. Its subspecialties cover all areas of plastic and cosmetic surgery, with distinctive strengths in breast reconstruction, lymphedema, localized scleroderma, scars and keloids, ear reconstruction, and chronic wound treatment.